<DOC>
	<DOCNO>NCT01537536</DOCNO>
	<brief_summary>The study hypothesis new drug EndoTAG-1 improve tumor volume reduction measure Magnetic Resonance Imaging add standard chemotherapy regimen weekly paclitaxel . This prospective single-center study investigate activity EndoTAG-1 + paclitaxel combination therapy patient HER2-negative breast cancer candidate receive chemotherapy surgery ( neoadjuvant chemotherapy ) .</brief_summary>
	<brief_title>Trial Neoadjuvant EndoTAG-1 Combination With Paclitaxel HER2-negative Breast Cancer</brief_title>
	<detailed_description>This prospective , single-center , open-label phase II clinical trial investigate activity EndoTAG-1 + paclitaxel combination therapy patient HER2-negative BC candidate neoadjuvant chemotherapy , measure decrease MRI-estimated tumour volume end EndoTAG-1 + paclitaxel administration . Patients stratify hormone receptor status . A total 20 female patient non-metastatic HER2-negative breast cancer candidate neoadjuvant chemotherapy meeting study eligibility criterion receive 12 weekly infusion EndoTAG-1 ( 22 mg/m2 liposomal paclitaxel ) combination paclitaxel ( 70 mg/m2 ) follow 3 cycle FEC ( Fluorouracil 500mg/m2 , Epirubicin 100mg/m2 , Cyclophosphamide 500mg/m2 ) every 3 week ( experimental group ) The study hypothesis EndoTAG-1 improve MRI- estimated volume reduction add weekly paclitaxel . The null hypothesis combination negligible effect volume reduction ( define low equal 50 % decrease ) versus alternative hypothesis combination yield least 80 % average decrease MRI- estimate volume end weekly paclitaxel EndoTAG-1 administration baseline</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1. newly diagnose histologically confirm BC breast infiltrate carcinoma histological grade &gt; 1 ( either operable , locally advanced inflammatory ) candidate neoadjuvant chemotherapy 2 . HER2negative tumor , define accord immunohistochemistry use fluorescent insitu hybridization ( FISH ) 3 . ECOG performance status 0 1 4 . Gender : female 5 . Age : &gt; = 18 year old 6 . Negative pregnancy test ( female childbearing potential ) 7 . Willingness perform doublebarriercontraception study 6 month post chemotherapy treatment ( female childbearing potential ) 8 . Signed informed consent 1 . Metastatic relapse disease 2 . Major surgery &lt; 3 week prior enrollment 3 . Severe pulmonary obstructive restrictive disease 4 . Uncontrolled inflammatory disease ( autoimmune infectious ) 5 . Clinically significant cardiac disease ( NYHA stadium &gt; 2 ) 6 . Results laboratory test ( hematology , chemistry ) outside specify limit : WBC ≤ 3 x 109/L ANC &lt; 1.5 x 109/L Platelets &lt; 100 x 109/L Hb ≤ 9.0 g/dl ( ≤ 5.6 mmol/l ) PTT/ INR &gt; 1.5 x ULN AST ALT &gt; 2.5 x ULN Alkaline Phosphatase &gt; 2 x ULN Total Bilirubin &gt; 1.5 x ULN 7 . Pregnancy nursing status 8 . Known positive HIV test 9 . Known hypersensitivity component EndoTAG1 , paclitaxel FEC formulation 10 . History malignancy breast cancer &lt; 5 year prior enrollment , except skin cancer ( i.e . basal squamous cell carcinoma ) treat locally 11 . History active significant neurological disorder psychiatric disorder would prohibit understanding give informed consent , would interfere clinical radiological evaluation central nervous system trial 12 . Concurrent treatment experimental product . Participation another clinical trial investigational product within 30 day prior study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Neoadjuvant chemotherapy</keyword>
	<keyword>EndoTAG-1</keyword>
</DOC>